NK Cell Therapy Post-Transplant

Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical Trial

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
15 patients (estimated)
Sponsors
Dana-Farber Cancer Institute
Tags
Natural Killer (NK) Cells (Allogeneic), Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1812
NCT Identifier
NCT06138587

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.